Marshall Wace, LLP Viatris Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Viatris Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 51,617 shares of VTRS stock, worth $582,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,617

Previous 1,101,101 95.31%

Holding current value

$582,239

Previous $11.7 Million 94.88%

% of portfolio

0.0%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$10.32 - $12.13 $10.8 Million - $12.7 Million	-1,049,484 Reduced 95.31%	51,617 $599,000
Q2 2024 Aug 14, 2024	BUY	$10.05 - $12.02 $11.1 Million - $13.2 Million	1,101,101 New	1,101,101 $11.7 Million
Q1 2023 May 15, 2023	BUY	$9.2 - $12.26 $3.34 Million - $4.45 Million	363,285 New	363,285 $3.49 Million
Q3 2022 Nov 14, 2022	BUY	$8.48 - $11.13 $3.85 Million - $5.05 Million	453,923 Added 115.53%	846,833 $7.22 Million
Q2 2022 Aug 15, 2022	SELL	$9.95 - $12.27 $76.6 Million - $94.4 Million	-7,697,266 Reduced 95.14%	392,910 $4.11 Million
Q1 2022 May 16, 2022	BUY	$9.81 - $15.4 $55.5 Million - $87.2 Million	5,662,076 Added 233.19%	8,090,176 $88 Million
Q4 2021 Feb 14, 2022	BUY	$12.09 - $14.68 $22.1 Million - $26.9 Million	1,830,042 Added 306.0%	2,428,100 $32.9 Million
Q3 2021 Nov 15, 2021	BUY	$13.25 - $15.13 $4.68 Million - $5.34 Million	353,137 Added 144.18%	598,058 $8.1 Million
Q2 2021 Aug 13, 2021	BUY	$12.97 - $16.15 $3.18 Million - $3.96 Million	244,921 New	244,921 $3.5 Million
Q1 2021 May 17, 2021	SELL	$13.59 - $18.54 $636,188 - $867,913	-46,813 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$14.3 - $18.74 $669,425 - $877,275	46,813 New	46,813 $877,000

Others Institutions Holding VTRS

# of Institutions

1,095

Shares Held

965M

Call Options Held

2.69M

Put Options Held

2.34M

View Full List

About Viatris Inc

Ticker VTRS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,212,669,952
Market Cap $13.7B
Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...

More about VTRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Viatris Inc Transaction History